News Focus
News Focus
Followers 469
Posts 30369
Boards Moderated 0
Alias Born 11/12/2016

Re: westener post# 55812

Saturday, 05/29/2021 11:44:49 AM

Saturday, May 29, 2021 11:44:49 AM

Post# of 77433
Bro, with the company now being debt free, and self sufficient

Your statement has zero credibility

$VDRM buy & hold for .40+ target in 2021

No More Toxics, No Debt, No Dilution

CEO States no need for Toxic financing going forward!!!

Pink "Current"

Up List OTCQB coming!

Revenues today - CEO states "Just scratching the surface"

Target Markets in the Billions Worldwide!

FDA Approved IP - Patent Protected

State Expansion coming! (8 going to 50)

Major Health Insurance Carrier Approval - 100's of hospitals, etc. FOR STARTERS!

https://www.globenewswire.com/news-release/2021/01/13/2157661/0/en/ViaDerma-Inc-Provides-Review-of-2020-and-Looks-Forward-to-2021.html

* The FDA approved the registration of a new 55 ml Vitastem spray bottle. This came at the request of hospitals that have tested the product. A larger spray version will be easier to apply the medication to large wounds.

* Liberdol, a new relief pain product was officially launched in 2020. The analgesics market in the U.S. is estimated to be more than $12 billion dollars.

* An extended line of credit was secured for financing future manufacturing. We anticipate sales to top 500,000 units in 2021.

* A large national hospital chain and a major health insurance company have completed successful testing of the Vitastem product. We are now in the final stages of discussions to determine the size of the initial purchase.

* Successful product testing was completed by a major midwestern university with whom we are also in discussions regarding their initial product purchase.

* We have initiated discussions with a major global medical nonprofit that has expressed interest in purchasing Vitastem for use by their doctors and medical staff in treating patients.

—————————

a target projection of 500,000 units sold for 2021 was given. If reached, multiplying by $79/unit = $39.5 m in revenue x 50% margins) = 20m earnings. At 20x earnings (for this growth) = a 400m market cap/1B= $.40 share target

Vitastem – Powerful Super-Healing Topical Antibiotic for Treating Infections, Wounds, Diabetic Ulcers, Bed Sores, Burns, Rashes, Acne and many other skin conditions.

https://www.amazon.com/dp/B076V2RM46/ref=cm_sw_r_cp_api_glt_fabc_YP194M5C6ASR4NN8J99D

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y